China Biobanking Market Research Report By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Application (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End Use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations) and By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage)- Forecast to 2035

China Biobanking Market Overview

As per MRFR analysis, the China Biobanking Market Size was estimated at 394.4 (USD Million) in 2023. The China Biobanking Market Industry is expected to grow from 411.2(USD Million) in 2024 to 1,020 (USD Million) by 2035. The China Biobanking Market CAGR (growth rate) is expected to be around 8.61% during the forecast period (2025 - 2035).

Key China Biobanking Market Trends Highlighted

There are certain big trends in the China Biobanking Market that will change the future. Government efforts to improve the healthcare system are one of the main things driving the industry. These efforts are leading to more research and development. The Chinese government has been pushing biobanking as a key part of precision medicine, which is leading to investments in infrastructure and technology. There is also increasing and more cooperation between private companies and universities to build biobanks that can help with genomics research and tailored medicine. 

As the need for high-quality biospecimens grows among pharmaceutical and biotechnology companies, new opportunities are opening up. As genetic research grows and biobanking technology improve, new collaborations and services become possible. Also, the growing number of older people and the rise in chronic diseases in China are making healthcare professionals use biobanks to better understand and treat these disorders. Recent developments also show that there is more of a focus on following the rules and being ethical when it comes to biobanking. As more people learn about data protection, stakeholders are putting money into open processes to gain trust. 

Also, biobanking activities are clearly moving toward digitalization in order to find better ways to organize and store data.The growing digital health sector in China supports this change by stressing how important it is to combine biobanking with digital technology to get the best research results and better treatment for patients. The overall picture shows that China is committed to using biobanking to improve public health and advance scientific research.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

China Biobanking Market Drivers

Rising Demand for Customized Medicine

In China, the push towards personalized and customized medicine is one of the primary drivers of the China Biobanking Market Industry. This trend is driven by advances in genomics and biotechnology, which foster the development of tailor-made treatments based on individual genetic profiles. According to the Ministry of Science and Technology of the People's Republic of China, the nation has seen a 30% increase in genetic testing services over the past five years, reflecting a growing acceptance of personalized medicine among healthcare providers and patients.

Major health organizations, such as the China National Center for Biotechnology Development, are investing significantly in research projects that utilize biobanking to enable the collection of biospecimens essential for developing precision therapies. This surge in demand for personalized healthcare solutions is likely to propel the biobanking sector further.

Increase in Chronic Diseases and Genetic Disorders

The prevalence of chronic diseases, such as cancer and diabetes, has been rising in China, creating a robust demand for biobanking services. Recent statistics from the National Health Commission of the People's Republic of China indicate that cancer has become the leading cause of death, with approximately 4.57 million new cases diagnosed annually, and rates are expected to continue increasing. 

This alarming trend drives the need for extensive research and development efforts to understand these diseases better and discover novel treatment options.Consequently, biobanks play a fundamental role in supporting research into population health and disease management, enabling researchers to access a diverse range of biological samples. The growing focus of organizations like the Chinese Cancer Society on cancer research emphasizes the pivotal role that biobanking holds in the fight against these chronic diseases.

Supportive Government Policies and Investments

The Chinese government has demonstrated steadfast support for the biobanking sector through favorable policies and significant investments. Initiatives aimed at promoting biotechnology and medical research have spurred growth in the China Biobanking Market Industry. For example, the 'Healthy China 2030' initiative outlines strategic objectives that encourage advancements in healthcare infrastructure, including biobanking facilities. 

Furthermore, the government allocated resources exceeding 200 billion CNY to bolster the biopharmaceutical industry, which includes biobanking as a critical component.Key government-backed institutions, such as the Chinese Academy of Medical Sciences, are actively involved in fostering biobanking initiatives, resulting in enhanced capacity to collect and utilize biosamples for research purposes. This proactive government stance affirms the importance of biobanking in improving public health and catalyzing innovations in healthcare.

China Biobanking Market Segment Insights

Biobanking Market Sample Type Insights

The Sample Type component of the China Biobanking Market is very important for the growth of healthcare, research, and biotechnology in the area. The government and commercial sector are putting more money into research and development, which is helping this market grow even faster. Blood products are one of the most important types of samples collected since they are used in transfusion treatment and research. This makes them a key part of many biobanks. Tissues, which are also very important, give researchers important information about how diseases progress and are very useful for investigations in regenerative medicine. 

Cells, especially stem cells, are becoming an important source for therapy and personalized medicine, offering possible remedies for diseases that were formerly thought to be impossible to treat. DNA and RNA, which are types of nucleic acids, are becoming more and more important for genetic research and finding biomarkers. They are also very important for precision medicine. Microbiome Samples have also become more popular, which shows that more people want to learn about how the human microbiome affects health and disease. The variety of sample types shows how different biobanking industries meet varied research goals and trends, making sure they stay useful as new technology and medical demands change.

China's commitment to quality and strict regulatory standards make the samples obtained even more reliable and strong. This sets the stage for new research that improves the health and well-being of the whole population. The increased cooperation between research organizations and academic institutions, which focuses on creating new methods and uses that make the most of the samples, also helps this segment stay active. The Sample Type segment of the China Biobanking Market is therefore a key driver of innovation, closing the gap between fundamental research and real-world, clinical applications that could really change healthcare in the region.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Biobanking Market Application Insights

The China Biobanking Market is significantly influenced by its Application segment, which plays a crucial role in advancing healthcare and research. Specifically, Research and Development serves as a foundational element, facilitating innovations in drug discovery and genomic studies that benefit from accessing diverse biological samples. Clinical Trials are integral, as they rely heavily on biobanked specimens to evaluate the efficacy and safety of new treatments, ensuring a robust pipeline of therapies. 

Personalized Medicine is gaining prominence, with the increasing emphasis on tailored treatments based on individual genetic profiles, thereby driving demand for biobanks that curate specific biospecimens.Regenerative Medicine is also a vital focus, as it leverages biobanked cells and tissues for therapies aiming to repair or replace damaged tissues and organs. Collectively, these applications highlight the importance of the China Biobanking Market by meeting the rising global demand for precision healthcare and innovative medical solutions. Moreover, advancements in technology and strong governmental support are changing the landscape, presenting vast opportunities for further growth in the region.

Biobanking Market End Use Insights

The China Biobanking Market is significantly influenced by its End Use segment, which includes various sectors such as Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations. Academic Research Institutions play a crucial role by utilizing biobanks for advancing scientific knowledge and supporting innovative research projects. Meanwhile, Biotechnology Companies leverage biobanking resources to accelerate product development and enhance their competitive edge in the market. Pharmaceutical Companies benefit from biobanks as they provide essential data and biological materials for drug discovery and development, thereby improving the efficiency of clinical trials.

Government Organizations focus on biobanking to support public health initiatives and regulatory frameworks while ensuring the ethical collection and use of biological samples. The importance of biobanking in China stems from the country’s investment in healthcare advancements and the increasing prevalence of chronic diseases. The growing demand for personalized medicine and the need for large-scale biological data further emphasize the significance of each sector within the End Use category. Collectively, these sectors drive the evolution and expansion of the China Biobanking Market, highlighting the interconnected nature of scientific research, healthcare, and biotechnology in the region.

Biobanking Market Storage Type Insights

The Storage Type segment of the China Biobanking Market plays a crucial role in preserving biological samples for research and clinical purposes. Vapor Phase Storage is gaining attention due to its ability to maintain temperature-sensitive materials at precise conditions, ensuring the longevity of samples such as tissues and cells. This method is particularly significant for various medical research applications, enabling advancements in personalized medicine. Liquid Phase Storage is also critical, as it allows for the immediate availability of samples for testing and analysis.

While it presents challenges in terms of energy consumption and operational costs, its ability to maintain a continuous cooling environment is invaluable. Cryopreservation Storage is another vital method that dominates in preserving reproductive cells and embryos, thereby supporting areas such as reproductive health and stem cell therapy. With increasing investments in research initiatives and healthcare in China, the demand for efficient storage solutions continues to rise. Overall, these storage methods contribute significantly to the ongoing development of the China Biobanking Market by ensuring the integrity and accessibility of biological materials essential for scientific advancement.

China Biobanking Market Key Players and Competitive Insights

The China Biobanking Market has grown and changed a lot in the last few years. This is because of new developments in biotechnology and genomics, as well as a growing need for biobanks to assist research in personalized medicine, clinical trials, and drug discovery. There is a lot of competition in this sector, with many companies trying to get a firm presence by offering services and capabilities that are different from those of their competitors. Technological innovation, following the rules, working with research institutes, and being able to keep high standards for collecting, storing, and processing samples are all important elements that affect competition. These things are very important for making sure that biobanking is reliable and ethical. This will draw in researchers and pharmaceutical companies who want to use biobanked specimens for their work. 

Tianjin Jinyao Group is a major player in the China Biobanking Market thanks to its deep knowledge of the biomedical field. The company's operations are supported by cutting-edge technology, like strong preservation methods and state-of-the-art lab facilities, which make sure that biological samples stay safe and used for a long time. This organizational strength is backed up by a strong dedication to research and development, which lets Tianjin Jinyao Group work with academic institutions and medical research facilities all around China. The company has grown its market presence and built a reputation for reliability and innovation in biobanking solutions through these partnerships. This gives it an advantage over its competitors.

Hua Medicine is another important company in the China Biobanking Market. It is known for offering a wide range of services that meet the demands of researchers and drug firms. The company specializes in biobanking different biological samples that are important for finding and developing new drugs. Its main goal is to improve the availability and quality of these resources. Hua Medicine's market presence is strengthened by its ongoing dedication to cutting-edge research, which has led to the successful deployment of new biobanking techniques. The company has also made smart mergers and acquisitions to improve its operations and add more services that are specific to the China region. This forward-thinking approach not only makes Hua Medicine more competitive, but it also strengthens its reputation as a trustworthy partner in the biobanking ecosystem, where it provides high-quality, ethically procured biological materials for research and therapeutic use.

Key Companies in the China Biobanking Market Include:

• Tianjin Jinyao Group


• Hua Medicine


• Sino Biopharmaceutical


• Huaan Biological Engineering


• Sinovac Biotech


• Fosun Pharma


• Beijing Tiantan Biological Products


• WuXi AppTec


• Shanghai Pharmaceuticals


• Guangdong Haojinghua


• Suzhou Abogen Biosciences


• Changchun BCHT Biotechnology


• Zhejiang Hisun Pharmaceutical


• China National Pharmaceutical Group

China Biobanking Market Industry Developments

In recent months, the China Biobanking Market has been witnessing significant developments. Notably, companies like Tianjin Jinyao Group and Hua Medicine have expanded their biobanking capabilities, enabling better access to biological samples for research purposes. The market's growth trajectory is further fueled by a surge in demand for biobanking services, especially in the context of personalized medicine and genomic research, facilitated by players such as Sinovac Biotech and Fosun Pharma. 

Mergers and acquisitions have also made headlines; for instance, in April 2023, WuXi AppTec acquired a controlling stake in Beijing Tiantan Biological Products, enhancing their capabilities in the biobanking sector. This consolidation reflects a broader trend in China, where companies such as Guangdong Haojinghua and Suzhou Abogen Biosciences are repositioning themselves to leverage new opportunities. 

The growth of the biobanking market is supported by favorable government policies and increased investment in Research and Development, with China's National Health Commission showing strong support for biobanking initiatives over the past few years, particularly during announcements in July 2022 regarding funding programs aimed at enhancing biotechnological infrastructure in the country.

China Biobanking Market Segmentation Insights

Biobanking Market Sample Type Outlook

• Blood Products


• Tissues


• Cells


• Nucleic Acids


• Microbiome Samples

Biobanking Market Application Outlook

• Research and Development


• Clinical Trials


• Personalized Medicine


• Regenerative Medicine

Biobanking Market End Use Outlook

• Academic Research Institutions


• Biotechnology Companies


• Pharmaceutical Companies


• Government Organizations

Biobanking Market Storage Type Outlook

• 
  

  Vapor Phase Storage

  
  


• 
  

  Liquid Phase Storage

  
  


• 
  

  Cryopreservation Storage

  
  

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	394.4(USD Million)
MARKET SIZE 2024	411.2(USD Million)
MARKET SIZE 2035	1020.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.61% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Tianjin Jinyao Group, Hua Medicine, Sino Biopharmaceutical, Huaan Biological Engineering, Sinovac Biotech, Fosun Pharma, Beijing Tiantan Biological Products, WuXi AppTec, Shanghai Pharmaceuticals, Guangdong Haojinghua, Suzhou Abogen Biosciences, Changchun BCHT Biotechnology, Zhejiang Hisun Pharmaceutical, China National Pharmaceutical Group
SEGMENTS COVERED	Sample Type, Application, End Use, Storage Type
KEY MARKET OPPORTUNITIES	Increased NGS applications, Government funding initiatives, Rising demand for personalized medicine, Expanding research collaborations, Growth in genetic testing services
KEY MARKET DYNAMICS	Regulatory changes, Technological advancements, Increasing demand for personalized medicine, Growing investment in healthcare, Rising awareness of biobanks
COUNTRIES COVERED	China